From: Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus
PCR
Week 0
Week 24 (SVR 12)
Week 36 (SVR24)
N
%
Positive
50
100.00
2
4.00
4
8.00
Negative
0
0.00
48
96.00
46
92
Total